Merck expects $5B to $6B in sales for COVID-19 antiviral this year

Merck sold $952 million of its COVID-19 antiviral pill, molnupiravir, in the fourth quarter of 2021 and this year expects to sell an additional $5 billion to $6 billion worth, CNBC reported Feb. 3.